# US 2023/0406827 A1 · Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406827 A1
- Document ID: US20230406827A1
- Status: Published application
- Kind: A1
- Application number: 18/157,592
- Filed: 2023-01-20
- Published: 2023-12-21
- Earliest claimed: 2019-08-09
- Assignees: Pfizer Inc.
- Applicants: Pfizer Inc.
- Inventors: Elaine GREER; Stephen ANDERSON; Mark MALONEY; Shu YU; Ekaterina ALBERT; Emily RIGSBEE
- Web page: https://patentgrep.com/patent/US20230406827A1

## CPC

- C07D 233/88: Nitrogen atoms, e.g. allantoin
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.

## Claims

### Claim at position 1

1-144. (canceled)

### Claim 145

A composition comprising a crystalline or amorphous form of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol-4-yl)pentanamide having a D[V,0.10] particle size between about 0.5 to about 15 μm, a D[V,0.50] particle size between about 2 to about 30 μm, a D[V,0.90] particle size between about 8 to about 600 μm, or a D[4,3] particle size of about 5 to about 200 μm.

### Claim 146 (depends on 145)

The composition of claim 145, wherein the (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol-4-yl)pentanamide has a D[V,0.50] of about 2 to about 30 μm.

### Claim 147 (depends on 145)

The composition of claim 145, wherein the (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol-4-yl)pentanamide has a D[V,0.50] of about 2 to about 25 μm.

### Claim 148 (depends on 145)

The composition of claim 145, wherein the (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol-4-yl)pentanamide has a D[V,0.50] of about 2 to about 20 μm.

### Claim 149 (depends on 145)

The composition of claim 145, wherein the (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol-4-yl)pentanamide has a D[V,0.50] of about 2 to about 15 μm.

### Claim 150 (depends on 145)

The composition of claim 145, wherein the (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol-4-yl)pentanamide has a D[V,0.90] of about 8 to about 600 μm.

### Claim 151 (depends on 145)

The composition of claim 145, wherein the (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol-4-yl)pentanamide has a D[V,0.90] of about 8 to about 200 μm.

### Claim 152 (depends on 145)

The composition of claim 145, wherein the (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol-4-yl)pentanamide has a D[V,0.90] of about 8 to about 100 μm.

### Claim 153 (depends on 145)

The composition of claim 145, wherein the (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol-4-yl)pentanamide has a D[V,0.90] of about 8 to about 75 μm.

### Claim 154 (depends on 145)

The composition of claim 145, wherein the (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol-4-yl)pentanamide is in the form of a hydrobromide salt.

### Claim 155 (depends on 145)

The composition of claim 145, wherein the composition comprises about 50 mg (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol-4-yl)pentanamide.

### Claim 156 (depends on 145)

The composition of claim 145, wherein the composition comprises about 100 mg (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol-4-yl)pentanamide.

### Claim 157 (depends on 145)

The composition of claim 145, wherein the composition comprises about 150 mg (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol-4-yl)pentanamide.
